Features of the new coronavirus COVID-19 infection in identical twins

Cover Page

Cite item

Full Text

Abstract

The problem of the clinical course and principles of treatment for the new coronavirus infection COVID-19 remains the most debated issue. At the same time, reliable prognostic criteria that determine characteristics of the disease course and outcome have not been established. Taking it into consideration, we present clinical cases of COVID-19 in identical twins. Patients A. and S., 39 years old, were admitted to the Regional Clinical Infectious Diseases Hospital. The patients were clinically diagnosed with COVID-19 coronavirus infection, verified, moderate form; bilateral polysegmental pneumonia of moderate severity, 1st degree respiratory failure. The course of COVID-19 coronavirus infection in identical twins markedly differed. Patient A. had peripheral blood lymphocytosis, slightly increased ESR, CRP, ferritin, IL-6, and D-dimer level. A paired twin brother (patient S.) had lymphopenia, ESR accelerated up to 20 mm/h, CRP pronouncedly increased up to 10 mg/ml, IL-6 — up to 9,5 pg/ml, and D-dimer — up to 750 ng/ml. Condition of the patient A. remained stable, on day 13th of treatment, the patient was discharged from the hospital. The condition of the patient S. on day 3rd of hospitalization deteriorated sharply. Considering the decrease in SpO2 level down to 88%, the damage of the lung parenchyma was more than 70%, resulting in the use of antibacterial drugs, anti-IL-6 monoclonal antibodies as well as selective reversible inhibitor of Janus-kinases 1 and 2. On day 16th of treatment, subjectively, the patient showed an improvement in general condition. During the next two days, the patient’s condition revealed marked positive dynamics on day 19th of hospital stay, the patient was discharged for rehabilitation. Thus, significant differences in the severity of the course of the new coronavirus infection in identical twins with similar medical history and lack of confounding comorbidities are most likely due to the initial dose of the viral load which was an important factor determining the development and course of infection.

About the authors

S. M. Yudina

Kursk State Medical University of the Ministry of Health of the Russian Federation

Email: ksmu-immunology@mail.ru
ORCID iD: 0000-0001-5074-9595
SPIN-code: 2234-5170

PhD, MD (Medicine), Professor, Head of the Department of Clinical Immunology, Allergology and Phthisiopulmonology

Russian Federation, Kursk

V. V. Kiseleva

Kursk State Medical University of the Ministry of Health of the Russian Federation

Email: vvkiseleva@icloud.com
ORCID iD: 0000-0002-4138-7673

PhD (Medicine), Associate Professor, Head of the Department of Infectious Diseases and Epidemiology

Russian Federation, Kursk

Tatyana S. Rusanova

Kursk State Medical University of the Ministry of Health of the Russian Federation

Author for correspondence.
Email: rusanova.tatiana046@mail.ru
ORCID iD: 0000-0003-2566-798X
SPIN-code: 4273-8540

PhD (Medicine), Associate Professor, Department of Clinical Immunology, Allergology and Phthisiopulmonology

Russian Federation, Kursk

I. A. Ivanova

Kursk State Medical University of the Ministry of Health of the Russian Federation

Email: ia.ivanova@mail.ru
ORCID iD: 0000-0002-7331-6255
SPIN-code: 9725-8582

PhD (Medicine), Associate Professor, Department of Clinical Immunology, Allergology and Phthisiopulmonology

Russian Federation, Kursk

References

  1. Баклаушев В.П., Кулемзин С.В., Горчаков А.А., Лесняк В.Н., Юсубалиева Г.М., Сотникова А.Г. COVID-19. Этиология, патогенез, диагностика и лечение // Клиническая практика. 2020. Т. 11, № 1. С. 7–20. [Baklaushev V.P., Kulemzin S.V., Gorchakov А.А., Lesnyak V.N., Ysubalieva G.M., Sotnikova A.G. COVID-19. Etiology, pathogenesis, diagnosis and treatment. Klinicheskaya praktika = Journal of Clinical Practice, 2020, vol. 11, no. 1, pp. 7–20. (In Russ.)] doi: 10.17816/clinpract26339
  2. Йокота Ш., Куройва Е., Нишиока К. Новая коронавирусная болезнь (COVID-19) и «цитокиновый шторм». Перспективы эффективного лечения с точки зрения патофизиологии воспалительного процесса // Инфекционные болезни: новости, мнения, обучение. 2020. Т. 9, № 4. С. 13–25. [Yokota Sh., Kuroyva E., Nishioka K. New coronavirus disease (COVID-19) and “cytokine storm”. Prospects for effective treatment from the point of view of the pathophysiology of the inflammatory process. Infektsionnye bolezni: novosti, mnenia, obuchenie = Infectious diseases: News, Opinions, Education, 2020, vol. 9, no. 4, pp. 13–25. (In Russ.)] doi: 10.33029/2305-3496-2020-9-4-13-25
  3. Костинов М.П., Шмитько А.Д., Полищук В.Б., Хромова Е.А. Современные представления о новом коронавирусе и заболевании, вызванном SARS-COV-2 // Инфекционные болезни: новости, мнения, обучение. 2020. Т. 9, № 2. С. 33–42. Kostinov M.P., Shmitko A.D., Polishchuk V.B., Khromova E.A. Modern ideas about the new coronavirus and the disease caused by SARS-COV-2. Infektsionnye bolezni: novosti, mnenia, obuchenie = Infectious diseases: News, Opinions, Education, 2020, vol. 9, no. 2, pp. 33–42. (In Russ.)] doi: 10.33029/2305-3496-2020-9-2-33-42
  4. Лобанова О.А., Трусова Д.С., Руденко Е.Е., Проценко Д.Д., Коган Е.А. Патоморфология новой коронавирусной инфекции COVID-19 // Сибирский журнал клинической и экспериментальной медицины. 2020. Т. 35, № 3. С. 47–52. [Lobanova O.A., Trusova D.S., Rudenko E.E., Protsenko D.D., Kogan E.A. Pathomorphology of a new coronavirus infection COVID-19. Sibirskiy zhurnal klinicheskoy i eksperimentalnoy meditsiny = Siberian Journal of Clinical and Experimental Medicine, 2020, vol. 35, no. 3, pp. 47–52. (In Russ.)] doi: 10.29001/2073-8552-2020-35-3-47-52
  5. Малинникова Е.Ю. Новая коронавирусная инфекция. Сегодняшний взгляд на пандемию XXI века // Инфекционные болезни: новости, мнения, обучение. 2020. Т. 9, № 2. С. 18–32. [Malinnikova E.Yu. New coronavirus infection. Today’s look at the pandemic of the XXI century. Infektsionnye bolezni: novosti, mnenia, obuchenie = Infectious diseases: News, Opinions, Education, 2020, vol. 9, no. 2, pp. 18–32. (In Russ.)] doi: 10.33029/2305-3496-2020-9-2-18-32
  6. Никифоров В.В., Суранова Т.Г., Чернобровкина Т.Я., Янковская Я.Д., Бурова С.В. Новая коронавирусная инфекция (COVID-19): клинико-эпидемиологические аспекты // Архивъ внутренней медицины. 2020. Т. 10, № 2. С. 87–93. [Nikiforov V.V., Suranova T.G., Chernobrovkina T.Ya., Yankovskaya Y.D., Burova S.V. New coronaviral infection (COVID-19): clinical and epidemiological aspects. Arkhiv vnutrenney meditsiny = The Russian Archives of Internal Medicine, 2020, vol. 10, no. 2, pp. 87–93. (In Russ.)] doi: 10.20514/2226-6704-2020-10-2-87-93
  7. Пащенков М.В., Хаитов М.Р. Иммунный ответ против эпидемических коронавирусов // Иммунология. 2020. Т. 41, № 1. С. 5–18. [Pashenkov M.V., Khaitov M.R. Immune response against epidemic coronaviruses. Immunologiya = Immunologiya, 2020, vol. 41, no. 1, pp. 5–18. (In Russ.)] doi: 10.33029/0206-4952-2020-41-1-5-18
  8. Романов Б.К. Коронавирусная инфекция COVID-2019 // Безопасность и риск фармакотерапии. 2020. Т. 8, № 1. С. 3–8. [Romanov B.K. Coronavirus disease COVID-2019. Bezopasnost i risk farmakoterapii = Safety and Risk in Pharmacotherapy, 2020, vol. 8, no. 1, pp. 3–8. (In Russ.)] doi: 10.30895/2312-7821-2020-8-1-3-8
  9. Смирнов В.С., Тотолян Арег А. Врожденный иммунитет при коронавирусной инфекции // Инфекция и иммунитет. 2020. Т. 10, № 2. С. 259–268. [Smirnov V.S., Totolian Areg A. Innate immunity in coronavirus infection. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2020, vol. 10, no. 2, pp. 259–268. (In Russ.)] doi: 10.15789/2220-7619-III-1440
  10. Федорова А.А., Кутепов Д.Е., Зубарев А.В., Пасечник И.Н. Комплексный подход к диагностике и лечению больного COVID-19 (клинический случай) // Кремлевская медицина. Клинический вестник. 2020. Т. 4. С. 114–117. [Fedorova A.A., Kutepov D.E., Zubarev A.V., Pasechnik I.N. An integrated approach to the diagnosis and treatment of a patient with COVID-19 (clinical case). Kremlevskaya meditsina. Klinicheskiy vestnik = Kremlin medicine. Clinical Bulletin, 2020, vol. 4, pp. 114–117. (In Russ.)] doi: 10.26269/c1my-ra52
  11. Ghomi R., Asgari N., Hajiheydari A., Esteki R., Biyabanaki F., Nasirinasab F. The COVID-19 pandemic: a systematic review of the current evidence. Russian Journal of Infection and Immunity, 2020, vol. 10, no. 4, pp. 655–663. doi: 10.15789/2220-7619-TCP-1508
  12. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, vol. 395, no. 10223, pp. 497–506. doi: 110.1016/S0140-6736(2)0/30183-5
  13. Jordan R.E., Adab P., Cheng K.K. Covid-19: risk factors for severe disease and death. BMJ, 2020, vol. 368: m1198. doi: 10.1136/bmj.m1198
  14. Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J.; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020, vol. 395, no. 10229, pp. 1033–1034. doi: 10.1016/S0140-6736(20)30628-0
  15. Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., Huang H., Zhang L., Zhou X., Du C., Zhang Y., Song J., Wang S., Chao Y., Yang Z., Xu J., Zhou X., Chen D., Xiong W., Xu L., Zhou F., Jiang J., Bai C., Zheng J., Song Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med., 2020, vol. 180, no. 7, pp. 934–943. doi: 10.1001/jamainternmed.2020.1429

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Yudina S.M., Kiseleva V.V., Rusanova T.S., Ivanova I.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).